Impaired Sensitivity to Thyroid Hormones Is Associated With the Change of Abdominal Fat in Euthyroid Type 2 Diabetes Patients: A Retrospective Cohort Study

Table 1

Characteristics of patients at baseline.

	Characteristics ()
At baseline
Age (years)	50.43 (11.86)
Duration (years)	4.5 (0.4, 10.9)
Male (, %)	554 (60.2)
Current smoker (, %)	313 (34.1)
Current drinker (, %)	374 (40.7)
Hypertension (, %)	366 (40.5)
BMI (kg/m^2)	26.98 (4.03)
VFA (cm^2)	108.21 (43.50)
SFA (cm^2)	209.63 (71.18)
Laboratory test
HbA1c	8.18 (2.69)
Cr (μmol/L)	67.26 (15.70)
LDL-c (mmol/L)	3.03 (0.90)
fT4 (pmol/L)	16.73 (1.97)
fT3 (pmol/L)	4.61 (0.61)
TSH (mIU/L)	1.83 (0.88)
Antihyperglycemic agent
Insulin/sulfonylureas (, %)	693 (75.2)
GLP1-RA/SGLT2i (, %)	34 (3.7)
At last visit of follow-up
BMI (kg/m^2)	26.92 (6.76)
VFA (cm^2)	106.94 (41.59)
SFA (cm^2)	200.15 (69.34)
Change of BMI (kg/m^2)	−0.07 (5.79)
Change of VFA (cm^2)	−1.27 (32.26)
Change of SFA (cm^2)	−9.48 (43.85)
Change rate of BMI (kg/m^2 per year)	0.14 (6.37)
Change rate of VFA (cm^2 per year)	−0.40 (18.04)
Change rate of SFA (cm^2 per year)	−4.52 (25.55)
Follow-up period (years)	2.2 (1.8, 3.0)

Abbreviations: BMI, body mass index; fT3, free triiodothyronine; fT4, free thyroxine; GLP1-RA, glucagon-like peptide-1 receptor agonists; LDL-c, low-density lipoprotein cholesterol; SFA, subcutaneous fat area; SGLT2i, sodium-glucose cotransporter 2 inhibitors; TSH, thyroid stimulating hormone; VFA, visceral fat area.